Bendamustine hydrochloride

SKU: orb1310942

Description

Bendamustine hydrochloride is a bifunctional alkylating agent with an IC50 of 50 µM, known for inducing DNA damage and apoptosis. It is widely used in research for studying hematological malignancies, both in vitro and in preclinical in vivo models.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 3543-75-7
• MW: 394.72
• Purity: 98.03% (May vary between batches)
• Formula: C₁₆H₂₁Cl₂N₃O₂·HCl
• SMILES: Cl.Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl
• Target: DNA/RNA Synthesis,DNA Alkylator/Crosslinker,Apoptosis
• Solubility: Ethanol:14 mg/mL (35.47 mM);H2O:2 mg/mL (5.07 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.07 mM);DMSO:60 mg/mL (152.01 mM)

Bioactivity

• Target IC50:
  DNA damage:50 μM
• In Vivo:
  Bendamustine causes more extensive and effective DNA single- and double-strand breaks than cyclophosphamide, Cisplatinum, or carmustine.Bendamustine inhibits mitotic assays and causes mitotic mega-mutations.Bendamustine regulates genes involved in apoptosis, DNA repair, and mitotic assays. Bendamustine had a very low teratogenic effect compared to an equimolar dose of Lomustine.26% of Bendamustine-treated MCF-7/ADR cells showed micronucleation compared to 6% of DMSO-treated cells. Bendamustine alone at concentrations ranging from 1 μg/mL to 50 μg/mL showed dose- and time-dependent effects with toxicity ranging from 30.4% to 94.8% observed after 48 hours. The LD50 of untreated and pretreated CLL cells was 7.3 or 4.4 μg/mL, respectively. Bendamustine treatment of SU-DHL-9 cells resulted in a 60% to 80% down-regulation of the mRNA expression of all three of these genes (polo-like kinase 1, Aurora kinase A, and cyclin B1). Bendamustine acts on non-Hodgkin's lymphocytes and uniquely regulates DNA repair pathways compared to other alkylating agents. Myeloid and breast cancer cells are resistant to Bendamustine, but HL-60 cells are moderately sensitive to Bendamustine.
• In Vitro:
  Bendamustine causes more extensive and effective DNA single- and double-strand breaks than cyclophosphamide, Cisplatinum, or carmustine.Bendamustine inhibits mitotic assays and causes mitotic mega-mutations.Bendamustine regulates genes involved in apoptosis, DNA repair, and mitotic assays. Bendamustine had a very low teratogenic effect compared to an equimolar dose of Lomustine.26% of Bendamustine-treated MCF-7/ADR cells showed micronucleation compared to 6% of DMSO-treated cells. Bendamustine alone at concentrations ranging from 1 μg/mL to 50 μg/mL showed dose- and time-dependent effects with toxicity ranging from 30.4% to 94.8% observed after 48 hours. The LD50 of untreated and pretreated CLL cells was 7.3 or 4.4 μg/mL, respectively. Bendamustine treatment of SU-DHL-9 cells resulted in a 60% to 80% down-regulation of the mRNA expression of all three of these genes (polo-like kinase 1, Aurora kinase A, and cyclin B1). Bendamustine acts on non-Hodgkin's lymphocytes and uniquely regulates DNA repair pathways compared to other alkylating agents. Myeloid and breast cancer cells are resistant to Bendamustine, but HL-60 cells are moderately sensitive to Bendamustine.
• Cell Research:
  SU-DHL-1 and SU-DHL-9 cells are preincubated for 30 minutes with either 6 mM methoxyamine or 50 μM O6-benzylguanine, inhibitors of Ape-1 base excision repair enzyme, or alkylguanyl transferase enzyme, respectively. The cells are then exposed to various concentrations of Bendamustine for 72 hours. Cytotoxicity is evaluated by the MTT viability assay and an IC50 is determined as the drug concentration that inhibited by 50% the viability value of the untreated control. Analyses are done.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Bendamustine, Bendamustine HCl, DNAAlkylator, DNA synthesis, DNA Synthesis, DNA Alkylator/Crosslinker, DNA Alkylator, DNASynthesis, Crosslinker, Apoptosis, antimetabolite, SDX 105, SDX105, SDX-105, SDX-105 (Cytostasane) HCl, EP 3101, EP3101, RNA Synthesis, RNASynthesis

Compound Identifiers

PubChem CID

77082